Study of progesterone-induced blocking factor in the treatment of women with threatening abortion, taking into account the polymorphism of the progesterone receptor gene.

O. S. Kryvopustov


Actual medical and social problem of modern obstetrics is threatening abortion. In its treatment, analogues of progesterone are used. Activation of progesterone receptors induces the production of anti-abortive protein-progesterone-induced blocking factor (PIBF). The dynamics of PIBF in 28 patients with the diagnosis of threatening abortion was analyzed. Women were treated by natural micronized progesterone depending on the features of the clinical course and single nucleotide polymorphism of the progesterone receptor gene rs590688. The quantitative content of PIBF in urine in pregnant women with threatening abortion was determined, namely, the increase in the content of this factor is associated with the prolongation of pregnancy. At the time of initiation of therapy, the concentration of PIBP was 28.8±1.5 (95% CI 26.7-29.2) ng/ml, and on the 7th day of therapy its concentration was 29.4±0.1 (95% CI 29.2-29.5) ng/ml. The increase in PIBF has reached a degree of statistical significance (T-W=15.0, p<0.001). In 27 (96.4%) patients who were pregnant, PIBP levels increased, 1 (3.6%) patient had spontaneous miscarriage on the 9th day of treatment. She had a decrease in concentration of PIBF in urine from 29.18 ng/ml at the time of admission to the hospital to 28.58 ng/ml on the 7th day of therapy. The study of progesterone-induced-blocking factor can be considered as an additional laboratory method of controlling progesterone therapy in women with threatening abortion in specialized research institutions.


threatened abortion; progesterone receptor gene polymorphism; progesterone induced blocking factor; natural micronized progesterone therapy

Full Text:



Vovk IB, Vdovychenko YP, Trokhymovych OV. [Early reproductive loss]. Kyiv. 2016;253. Ukrainian.

Gnatko OP, Kryvopustov OS. [Threatened abor­tion treatment efficacy depending on progesterone recep­tor gene polymorphism]. Bukov. med. visn. 2017;21(1):44-8. Ukrainian.

Gnatko OP, Kryvopustov OS. [Effectiveness of evaluation of progesterone therapy in women with threa­tened abortion based on clinical approach and single nuc­leotide polymorphism progesterone gene receptor rs590688]. Eksperym. i klin. medytsyna. 2017;1:71-6. Ukrainian.

Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990;11(2):266-301.

Dosiou C, Giudice LC. Natural killer cells in preg­nancy and recurrent pregnancy loss: endocrine and im­munologic perspectives. Endocr Rev. 2005;26(1):44-62.

Kelemen K, Bognar I, Paal M, Szekeres-Bartho J. A progesterone-induced protein increases the synthesis of asymmetric antibodies. Cell Immunol. 1996;167(1):129-34.

Manuck TA, Lai Y, Meis PJ, Dombrowski MP, Sibai B, Spong CY, et al. Progesterone receptor po­lymorphisms and clinical response to 17-alpha-hyd­roxyprogesterone caproate. Am J Obstet Gynecol. 2011;205(2):135.e1-9.

Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Proges­te­rone-induced blocking factor (PIBF) modulates cytokine pro­duc­tion by lymphocytes from women with recurrent mis­ca­rriage or preterm delivery. J Reprod Immunol. 2009;80(1/2):91-9.

Romano A, Delvoux B,FischerDC, Groothuis P. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol. 2007;38(1/2):331-50.

Szekeres-Bartho J, Wegmann TG. A progeste­rone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol. 1996;31(1/2):81-95.

Wahabi HA, Abed Althagafi NF, Elawad M, Al Zei­dan RA. Progestogen for treating threatened misca­rriage. Cochrane Database Syst Rev. 2011;16(3):CD005943.

GOST Style Citations

1.       Вовк І.Б. Раннірепродуктивнівтрати / І.Б. Вовк, Ю.П. Вдовиченко, О.В. Трохимович. – Київ, 2016. – 253 с.

2.       Гнатко О.П. Ефективність прогестеронової те­рапії у жінок із загрозливим абортом залежно від поліморфізму гена рецептора прогестерону / О.П. Гнатко, О.С. Кривопустов // Буковин. мед. віс­ник. – 2017. – Т. 21, № 1 (81). – С. 44–48.

3.       Гнатко О.П. Оцінка ефективності прогестеро­нової терапії загрозливого аборту на підставі клініко-генетичного підходу з урахуванням алельного полі­морфізму гена рецептора прогестерону rs590688 / О. П. Гнатко, О. С. Кривопустов // Експерим. і клініч. медицина. – 2017. – № 1 (74). – С. 71–76.

4.       Clark C. Progestin regulation of cellular proli­feration / C. Clark, R. Sutherland // Endocrine. – 1990. – N 11. – P. 266–301.

5.       Dosiou C. Natural killer cells in pregnancy and recurrent pregnancy loss. Endocrine and immunologic perspectives / C. Dosiou, L. Giudice // Endocr Rev. – 2005. – N 26. – P. 44–62.

6.       Kelemen K. A progesterone-induced protein increases the synthesis of asymmetric antibodies / K. Kelemen, I. Bognar // Cell Immunol. – 1996. – Vol. 167. – P. 129–134.

7.       Manuck T. A. Progesterone receptor polymo­rphisms and clinical response to 17-alpha-hydroxypro­gesterone caproate / T. A. Manuck, Y. Lai, P. J. Meis // Am. J. Obstet. Gynecol. – 2011. – Vol. 205. – P. 135.

8.       Raghupathy R. Progesterone-induced blocking fac­tor (PIBF) modulates cytokine production by lympho­cytes from women with recurrent miscarriage or preterm delivery / R. Raghupathy, E. Al-Mutawa, M. Al-Azemi // J Reprod Immunol. – 2009. – Vol. 80. – P. 91-99.

9.       Romano A. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone / A. Romano, B. Delvoux, D. Fischer // J. Mol. Endocrinol. – 2007. – Vol. 38. – P. 331-350.

10.    Szekeres-Bartho J. A progesterone-dependent im­munomodulatory protein alters the Th1/Th2 balance / J. Szekeres-Bartho, T. Wegmann // J Reprod Immunol. – 1996. – Vol. 31. – P. 81-95.

11.    Wahabi H. Progestogen for treating threatened mis­car­riage / H. Wahabi, A. Abed // Cochrane Database Syst Rev. – 2011.



  • There are currently no refbacks.